EB613
Osteoporosis (postmenopausal women)
Key Facts
About Entera Bio
Entera Bio is pioneering the oral delivery of biologics, a significant challenge in pharmaceutical development. Its core platform technology is designed to facilitate the gastrointestinal absorption of large molecules, potentially transforming treatment paradigms for chronic conditions requiring frequent injections. The company's most advanced candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, have demonstrated proof-of-concept in clinical trials. Entera's strategy focuses on developing oral formulations of established peptide hormones to create more patient-friendly therapies.
View full company profile